# Novelty Audit S0 v4 — Sweet Trap Evolutionary Reframing

**Audit date:** 2026-04-21
**Stage:** S4 (Stage-Gate pipeline, non-negotiable)
**Current target journal:** Proceedings of the Royal Society B (primary); eLife Reviewed Preprint (backup); Current Biology Report (reformat-ready)
**Auditor:** novelty-audit agent (independent; does NOT endorse research-director or literature-specialist positions)
**Pass threshold:** ≥ 65 / 100
**Inputs read:** research_question_and_hypotheses.md, evidence_architecture_v4.md, analytical_pipeline.md, journal_matching_v4.md, competing_literature_map.md, competing_literature_landscape_v4.md, public_data_feasibility_v4.md, stage0_decision_memo.md, WORKLOG.md §2026-04-20, hssc_hostile_review.md

---

## Part 1: 10-Item Novelty Checklist (Independent Scoring)

Each item scored 0–10. Evidence-based, not narrative.

### 1. Problem novelty — **4 / 10**

**Claim:** "Sweet Trap is biologically universal + evolutionarily formed."

**Independent view:** The *problem itself* — reward-fitness decoupling across taxa produced by evolutionary history — is **not new**. It is the core problem of the evolutionary-trap / ecological-trap / HIREC / evolutionary-mismatch / sensory-exploitation / supernormal-stimulus literatures combined. Robertson & Chalfoun 2016, Hale & Swearer 2016, Bauer & Sih 2020, Nesse 2005/2019, Li & van Vugt 2018, and Ryan & Cummings 2013 collectively cover ~90% of the conceptual territory. Your own competing_literature_landscape_v4.md §1 acknowledges this ("Ecological Trap ⊂ MST ⊂ Sweet Trap").

**What saves it from 2/10:** The *integration* — asking one question across humans, 50+ animals, and molecular phylogeny simultaneously — is a framing choice not yet executed in a single paper. Robertson has the animals; Nesse has the humans; no one has stapled the molecular conservation layer onto either. That staple is genuinely a novel problem *statement*, even if each piece is prior art.

**Deductions:** This is a synthesis problem, not a discovery problem. A Proc B editor who reads Hale & Swearer 2016 will ask "what new question is being asked?" and your answer ("is susceptibility phylogenetically signalled?") is a methodological refinement of Hale & Swearer's open questions, not a new biological question.

---

### 2. Framework / construct novelty — **3 / 10**

**Claim:** F1–F4 conditions + A1–A4 axioms + Δ_ST = U_perc − E[U_fit] as a biological framework.

**Independent view:** Harsh but necessary. The F1–F4 / A1–A4 / Δ_ST formalism was constructed for the **policy-domain paper** (v3.x). In v4 you are lifting it and re-purposing it as a "biological operational measure." But:

- **Δ_ST = U_perc − E[U_fit]** is a re-labelling of the Robertson-Hutto two-condition test (high attractiveness, lower fitness) that Hale & Swearer 2016 already implement quantitatively. Your "continuous scalar" framing is a methodological gloss over an existing effect-size metric (attractiveness-fitness differential). Competing_literature_map.md §1.1 admits Hale & Swearer 2016 is exactly the closest antecedent.
- **F2 (voluntary endorsement)** is the only genuinely novel conceptual addition. It usefully distinguishes Sweet Trap from coerced-exposure HIREC. But in a biology paper, "voluntary endorsement" is a contested anthropomorphism when applied to moths, cnidarians, or annelids. Proc B reviewers will ask: how do you operationalise "endorsement" in a jellyfish? You have no answer.
- **A1–A4 axioms** are not axioms in the mathematical sense (no model deductively follows from them); they are named assumptions. In the v3.x policy paper they supported T2, which is being dropped in v4. Without T2, the axiomatic scaffolding is decoration.

**What saves it from 1/10:** F2 + the voluntary-vs-coerced distinction IS a real conceptual clarification of a genuine HIREC-literature conflation. This is worth 2–3 points.

**Deductions:** Dropping T2 but keeping the axiomatic framing is structurally incoherent — the axioms existed to prove the theorem. A hostile Proc B reviewer ("why present axioms without deriving anything from them?") will notice.

---

### 3. Empirical data novelty — **5 / 10**

**Claim:** Three Parts pooled — humans (6 cohorts, 5 ancestries) + 50+ animal cases + molecular phylogeny across ≥6 phyla.

**Independent view:**

- **Part 1 (humans):** All data sources are public and already analysed extensively. NHANES, UKBB, HRS, ELSA, SHARE, Add Health, FinnGen, BBJ, MVP, AoU — every single one has hundreds of published MR / meta papers. Your integration-across-cohorts is execution, not data novelty. Trans-ancestry MR on metabolic/psychiatric traits is the active research program of at least 5 labs (Mahajan, Atkinson, Martin, Chen, Tsuo). You will not be first to publish trans-ancestry MR on reward-related phenotypes.
- **Part 2 (animals):** 50+ cases from a literature pool of ~500 papers = execution, not data novelty. Santos 2021 Zenodo + Hale & Swearer 2016 review list already aggregate most of the candidate cases. Your novelty here is the **coding framework (F1+F2)** applied to those cases, not the cases themselves.
- **Part 3 (molecular):** Ensembl + OrthoDB + UniProt queries on dopamine / opioid / TAS1R / orexin orthologs. This has been done many times (Yamamoto & Vernier 2011; Feijó et al. 2019; dozens of receptor-specific papers). Cross-phylum dN/dS on reward receptors *as a package* is mildly novel, but Part 3 itself acknowledges this (evidence_architecture_v4.md §4.1 references Yamamoto & Vernier 2011).

**What saves it:** The *combination* of all three data layers in a single pre-registered pipeline is genuinely uncommon. Single-paper integration of trans-ancestry human MR + 50-case animal meta + cross-phylum molecular phylogeny — I cannot name a direct precedent.

**Deductions:** None of the three Parts uses data that is private, original, or unavailable to any other researcher with the same skill set. "Execution-novelty" not "data-novelty."

---

### 4. Methodological novelty — **6 / 10**

**Claim:** Phylogenetic signal (K, λ) + SIMMAP ancestral reconstruction + PGLS + branch-site dN/dS + trans-ancestry MR-APSS integrated.

**Independent view:** This is where v4 is strongest. Let me score it carefully:

- **Phylogenetic signal on Δ_ST:** You claim "no prior paper has performed a phylogenetic-signal test on susceptibility magnitude in the ecological-trap literature." I stress-tested this against Guo et al. 2024 Proc B (phylogenetic signal in predation response) and Sánchez-Tójar 2020 (phylogenetic signal in mate choice). Neither targets reward-fitness decoupling. **The specific analytical target is novel.** BUT the *method* (K, λ, PGLS, SIMMAP) is entirely standard since Blomberg 2003; nothing methodological is new.
- **Cross-phylum dN/dS on reward receptors:** Method is PAML 2007; application to reward receptors has been done (Feijó 2019 for TAS1R, multiple for DRD). The **genome-wide baseline** (Z-score of reward-receptor ω against matched random orthologs) is a mild methodological refinement — helpful but not novel.
- **Trans-ancestry MR-APSS:** Hu et al. 2022 method; routine in 2024–2026.
- **Three-layer pre-registered integration:** The integration is the novel move, not any individual step.

**What this scores:** The novelty is **applying standard phylogenetic-comparative methods to a new empirical target (Δ_ST)**. That is a legitimate methodological contribution of the sort Proc B regularly publishes. But it is a *small* methodological advance — "first K/λ estimate for X" is a common Proc B paper archetype that typically yields a 6/10 not a 9/10.

**Deductions:** You are not inventing a new estimator, new identification strategy, or new measurement technology. You are applying 2003-era methods to a 2016-era case list.

---

### 5. Cross-species evidence breadth — **7 / 10**

**Claim:** 50+ cases across 7 taxonomic classes (planned; currently 20 in v2 meta).

**Independent view:** This is a clear strength, and is the one component that genuinely approaches top-field novelty.

- Santos et al. 2021 *Science* (138 species, one domain = plastic ingestion) is the only comparable-scale cross-species meta in the adjacent literature.
- Hale & Swearer 2016 covered ~43 cases but only in ecological-trap context without Δ_ST operationalisation.
- Your claim of 7 taxonomic classes / ≥6 phyla is ambitious: Chordata + Arthropoda + Mollusca + Cnidaria + Annelida is 5, and the feasibility document shows Arthropoda + Chordata cases dominate your current 20-case set. Getting to Cnidaria and Annelida cases with quality F1+F2 evidence will be hard.

**Score justification:** If executed at 50 cases × ≥5 phyla with ≥3 non-tetrapod-non-insect phyla represented, this is a 7. If executed at 30 cases × 3 phyla (the realistic scenario given feasibility document yield estimate of "30+ cases if systematic search executed"), this drops to a 4.

**I am scoring the stated target, but flag: the document's feasibility estimate is 30+, not 50+. There is an internal inconsistency between ambition (50+ across 7 classes) and realism (30+ if exhaustive).**

---

### 6. Formal rigour — **3 / 10**

**Claim:** A1–A4 axioms + pre-registered predicted magnitudes + explicit falsification criteria.

**Independent view:** Weak.

- **Axioms without theorems.** With T2 dropped, the axiomatic framing is decorative, not deductive. An evolutionary-biology paper does not need axioms; an evolutionary-biology paper needs **hypotheses with measurable predictions**, which you have (H1–H5). Presenting A1–A4 as axioms while not deriving anything from them invites the Proc B reviewer objection "what role do these axioms play?"
- **No formal evolutionary model.** You claim evolutionary conservation causes Sweet Trap but provide no population-genetic model, no drift-selection-mutation balance argument, no ESS analysis, no Price equation decomposition. Compare to Kokko's theoretical work (cited as reviewer) which does present formal models. A Kokko-style reviewer will ask: where is the mechanistic model that predicts K > 0.3?
- **Falsification criteria (H1–H5) are adequately specific.** This is good. 1 point for this.
- **Predicted magnitudes table** (evidence_architecture_v4.md §6) is pre-registration-quality. 2 points for this.

**Deductions:** You are using the *language* of formal rigour (axioms, theorems, falsification criteria) without the *substance* (a deductively-generating model). This will be read as scientism by a rigorous theoretical reviewer.

---

### 7. Testability / falsifiability — **8 / 10**

**Claim:** H1–H5 with explicit falsification criteria; failure modes specified in dependency table.

**Independent view:** This is genuinely strong. H1–H5 failure modes are specified in advance. The dependency table (H2 load-bearing; H3 failure → convergent reframing; H4 failure → restricted claim) is exemplary pre-registration design. H3's "null is publishable, just reframed" handling is particularly honest.

**Deductions (–2):** H5 is under-specified (sample size for PGLS is stated as N ≥ 30 mammalian+bird, but power analysis not provided). H1 "any two of three null" criterion is loose — the three streams are not independent; a common confounder (e.g., cohort-specific measurement error) could null all three. But these are minor relative to the overall falsifiability design.

---

### 8. Delta vs closest competitors — **5 / 10**

Closest competitors and honest delta assessment:

- **Robertson & Chalfoun 2016** (wildlife evolutionary trap review): Your delta = (a) phylogenetic signal test, (b) 50+ cases vs their conceptual review, (c) human extension, (d) molecular layer. Real delta: **methodological + scope**. Robertson did not attempt quantitative analysis.
- **Hale & Swearer 2016** *Proc R Soc B* (the most threatening competitor — same journal, same taxa scope, systematic review): Your delta = (a) K/λ test, (b) Δ_ST as continuous scalar (they already used attractiveness-fitness difference), (c) molecular conservation layer, (d) humans. Real delta: **moderate**. Their paper already did PRISMA + 43 cases + documented the quantification gap — you are explicitly filling the gap they identified. That is a credit and a risk: editor may read your paper as "Hale & Swearer 2016 Part 2."
- **Li & van Vugt 2018** *Curr Dir Psychol Sci* (human mismatch multi-domain): Your delta = cross-species + quantitative. Real delta: **large** (they are human-only, conceptual).
- **Ryan & Cummings 2013** *Ann Rev Ecol Evol Syst* (sensory traps, cross-species): Your delta = (a) decoupling framework beyond mate choice, (b) K/λ test, (c) humans. Real delta: **moderate**. Their paper covers cross-species sensory exploitation thoroughly; your Δ_ST framing recasts rather than extends.
- **Santos et al. 2021** *Science* (138 species, plastic ingestion): Your delta = multi-domain (not just plastic). Real delta: **moderate scope extension**, not a novel finding.

**Aggregate delta assessment:** Sweet Trap v4's contribution is **operational quantification + phylogenetic-signal test + integration** across prior literatures. Is this enough for Proc B editor to say "this is a clear advance"?

**My honest answer: probably just barely, conditional on execution.** The phylogenetic-signal novelty is real but small. The integration novelty is real but "integration" is a lower-prestige novelty type in evolutionary biology. A Proc B editor who specializes in evolutionary trap work will either see this as "the paper we've been waiting for" (sympathetic) or "a competent extension of Hale & Swearer" (neutral-to-cool). This is a coin-flip delta.

**Score: 5/10.**

---

### 9. Potential impact — **5 / 10**

**If accepted in Proc B, expected citation trajectory:**

- Proc B evolutionary-trap papers in 2015–2020 cohort (e.g., Hale & Swearer 2016, Sih 2011) accumulated 150–500 citations each. Median is ~200 cites at 10 years.
- A Proc B paper claiming "phylogenetic signal in Sweet Trap" with a quantitative result and a unified framework has plausible 5-year trajectory of 50–150 cites.
- If K/λ results are strong (K > 0.5), paper becomes a reference point for the field and could reach 300+ cites.
- If K/λ results are moderate (0.1 < K < 0.3), paper is a modest contribution, ~50 cites at 5 years.

**Application potential:** You have explicitly excluded policy/welfare claims. Fine for biology, but limits cross-disciplinary pickup.

**Score 5/10** reflects: the expected-value outcome is a "solid Proc B contribution," which is a reasonable 5/10. Top Proc B papers that re-define subfields would score 7–8; specialist-only papers score 3–4.

---

### 10. Risk of "已被做过" / preprint collision — **6 / 10**

Independent check on competing_literature_landscape_v4.md claim "no such paper exists":

- **Verified:** No published paper combines cross-phyla meta + phylogenetic signal + trans-ancestry MR + molecular conservation. The literature landscape document is correct on this.
- **Unverified risk:**
  - Nesse group synthesis (noted as "LOW-MEDIUM risk" in landscape doc). You do not appear to have searched bioRxiv, PsyArXiv, or EcoEvoRxiv in the last 6 months for competing preprints. Given the 12-week submission horizon, this is a must-check before Week 0 pre-registration.
  - Robertson lab output (noted as "LOW"). Robertson has published 2–3 evolutionary-trap papers annually 2020–2025. No synthesis claiming cross-phyla universality, but this should be verified at S5 not assumed.
  - Hale, Swearer, Sih labs: probability of a competing phylogenetic-signal paper appearing in 12–18 months is non-zero. Your landscape doc estimates 6–12 months to a competing paper from a well-funded lab. You have ~3 months (12 weeks to submission).

**Score 6/10:** Field is relatively uncrowded for the specific phylogenetic-signal-on-Δ_ST combination. Collision risk is real but not paralyzing if you execute quickly and pre-register Week 0 to establish priority on bioRxiv.

**Deduction:** I have not independently verified that no similar paper exists on bioRxiv / EcoEvoRxiv / PsyArXiv / Authorea as of April 2026. This verification should happen **before** the Week 0 OSF deposit.

---

## Part 1 Summary

| # | Criterion | Score |
|---|-----------|-------|
| 1 | Problem novelty | 4 |
| 2 | Framework / construct novelty | 3 |
| 3 | Empirical data novelty | 5 |
| 4 | Methodological novelty | 6 |
| 5 | Cross-species evidence breadth | 7 |
| 6 | Formal rigour | 3 |
| 7 | Testability / falsifiability | 8 |
| 8 | Delta vs closest competitors | 5 |
| 9 | Potential impact | 5 |
| 10 | Risk of "已被做过" | 6 |
| | **TOTAL** | **52 / 100** |

**Pass threshold: 65 / 100. v4 scores 52. GATE NOT PASSED.**

---

## Part 2: Top 3 Novelty Highlights vs Top 3 Risks

### Top 3 Genuine Highlights

1. **H3 phylogenetic-signal test on Δ_ST is a real novelty claim** (Item 4). First-ever K/λ estimate for reward-fitness decoupling susceptibility at cross-phyla scale. This IS a clear Proc B paper in itself if N ≥ 50 is achieved and the result is interpretable regardless of direction.

2. **Testability / falsifiability architecture is exemplary** (Item 7). The H1–H5 dependency table with graceful degradation pathways (H3 null → convergent reframing; H4 null → clade-specific) is genuinely high-quality pre-registration design. This alone reduces rejection risk by 5–10 pp.

3. **F2 (voluntary endorsement) distinction from HIREC-coerced-exposure** (Item 2 partial credit). This is the one genuinely new conceptual move. If developed with a clean operationalisation for non-vertebrates, it becomes a legitimate contribution. Currently underdeveloped.

### Top 3 Substantive Risks

1. **The axiomatic scaffolding has been orphaned by T2's removal.** A1–A4 existed to prove T2. Without T2, presenting axioms in a biology paper invites the objection "why are there axioms here?" — a signal of formalism without substance. **Action required:** Either drop A1–A4 from main text (move to SI as definitional glossary) or develop at least one derivable prediction from them.

2. **Part 3 (molecular conservation) is the weakest novelty claim, not the strongest.** Your feasibility document (public_data_feasibility_v4.md §Part 3) states the key argument is actually about **convergent functional architecture** (absence of strict orthology across phyla), not deep sequence conservation. This contradicts H4 ("dN/dS < 0.15"). **You have a factual tension in the pipeline: the data says "insects have no TAS1R orthologs, dopamine receptors are only ~40–50% identical insect-vertebrate" while H4 predicts deep conservation. This is not conservation; this is convergence + divergence.** A molecular-evolutionist reviewer will catch this immediately. **Consider this a potential fatal design flaw, not a routine risk.**

3. **Feasibility-ambition gap on Part 2.** H2 requires 50+ cases across ≥6 phyla. Feasibility doc estimates "30+ cases if systematic search executed" and 7 taxonomic classes currently concentrated in Chordata + Arthropoda. The gap between 30+ and 50+ is load-bearing because H2 is the critical path. **Risk:** At Week 4 GATE 1 feasibility check you discover you have 32 cases across 4 classes, and you need to either (a) lower the N ≥ 50 threshold retroactively (pre-registration violation) or (b) accept a "30+ cases across 5 classes" headline that is not differentiated enough from Hale & Swearer 2016.

---

## Part 3: Journal Match Assessment

### Proc R Soc B — Primary

**Novelty ceiling for Proc B acceptance**: approximately 60–65 on my scale. Proc B is a Top Field journal but not a flagship; it publishes solid comparative-biology contributions with methodological rigour, not discovery papers.

**v4 at 52/100: Below Proc B acceptance threshold.** Not desk-reject territory (Proc B desk-rejects are typically 30–40 scores), but review-stage reject probability at 52 is high (~50–60%).

**Delta vs Robertson & Chalfoun 2016:** My Item 8 score (5/10) says this delta is borderline "clear advance." A Proc B handling editor reading the paper alongside Hale & Swearer 2016 is likely to ask: "Where is the one decisive finding?" You have H3 (phylogenetic signal), but H3 is not yet executed and its predicted magnitude (K = 0.3–0.8) spans "weak signal" to "strong signal" — the paper's headline depends on which end of that range you land at.

### eLife Reviewed Preprint — Recommended instead

Given the 52 score and the Reviewed-Preprint structural advantage (paper publishes regardless of verdict, with reviewers' assessments attached), **eLife is a better primary target than Proc B at this novelty level**. Reasons:

- 52/100 gets you a "Valuable with Solid evidence" at worst, which is still a citable publication.
- Public review process turns the "integration novelty" into an asset (reviewers judge on multiple dimensions, not a single accept/reject).
- No desk-reject anxiety in the Proc B / Curr Biol sense.

### Current Biology Report — Reformat-ready second

Only viable **if** H3 produces K > 0.5 at Week 5–6. Short-form requires one decisive finding; 52/100 average doesn't reformat to a single punchline unless one sub-component lands strongly.

### Fatal mismatch check: Nature Ecology & Evolution

You correctly evaluated NEE and rejected it (65% desk reject). At 52/100, NEE is **explicitly outside scope**. Do not submit.

---

## Part 4: Improvement Paths — How to Reach 65

Three prioritised paths, ranked by expected Novelty-score lift per unit of Week-effort:

### Path A (+8 points, 2 weeks): Resolve Part 3 conservation-vs-convergence contradiction

**Problem:** H4 predicts deep conservation (dN/dS < 0.15, ≥6 phyla orthologs). Feasibility data says insects lack TAS1R orthologs and have divergent (40–50% identity) dopamine receptors. This is convergence, not conservation.

**Fix:** Reframe Part 3 as "**convergent functional architecture of reward signalling across phyla, with within-phylum conservation at the Bilaterian origin.**" This is a *more* novel claim than deep conservation (which is already documented by Yamamoto & Vernier 2011), and it harmonises with the data.

**Score impact:** Item 1 (+2), Item 2 (+1), Item 4 (+2), Item 8 (+3) = +8.

### Path B (+5 points, 3 weeks): Derive H3 prediction from a formal model

**Problem:** H3 (K > 0.3) is a free prediction — it is not derived from any mechanistic model. You predict K > 0.3 because "behavioural-ecology traits typically show K > 0."

**Fix:** Write a one-page Price-equation / ESS-style argument that *predicts* K > 0.3 for susceptibility traits that depend on deeply-conserved receptor machinery. This transforms H3 from a descriptive prediction to a model-derived test.

**Score impact:** Item 2 (+1), Item 6 (+3), Item 8 (+1) = +5.

### Path C (+4 points, 1 week): Pre-registration + bioRxiv deposit before Week 0

**Problem:** No independent verification that a competitor paper is not on bioRxiv.

**Fix:** (a) Run comprehensive bioRxiv / EcoEvoRxiv / PsyArXiv / Authorea search in Week 0. (b) Deposit a 4-page pre-registration preprint on bioRxiv simultaneously with OSF, establishing priority publicly. (c) Add the DOI to future submissions.

**Score impact:** Item 10 (+2), Item 9 (+2 via credibility of priority) = +4.

### Aggregate: Paths A + B + C = +17 points → 69/100. Passes the 65 threshold.

**Fork #1 assessment (rebuild S3 evidence architecture):** Not recommended. Paths A+B+C fix the design without rebuilding. Fork #1 would consume 4–6 weeks and lose the existing 20-case / MR chain / ortholog assets.

---

## Part 5: Final Verdict

**Score: 52 / 100.**

**Passes S4 gate ( ≥ 65 )? NO.**

**Recommended primary journal (current state):** eLife Reviewed Preprint, not Proc R Soc B. At 52/100, Proc B carries substantial send-to-review-then-reject risk (~50–60%) that wastes the 12-week timeline.

**Recommended primary journal (post Paths A+B+C, ≈69/100):** Proc R Soc B primary is viable. eLife remains reasonable backup.

**Action required:** Return to S1 (design revision), NOT S5 (launch). Specifically:

1. **Execute Path A (Part 3 reframing)** within 2 weeks. This is a design decision, not execution. Rewrite evidence_architecture_v4.md §4 with convergent-functional-architecture framing. Update H4 falsification criterion accordingly.
2. **Execute Path B (formal H3 derivation)** within 3 weeks. This unblocks the "formalism without substance" concern.
3. **Execute Path C (bioRxiv priority deposit)** before Week 0 OSF pre-registration.
4. **Re-audit at S4.v2** after Paths A+B+C complete. Expected score 68–70. Gate passes.
5. **Resolve feasibility-ambition gap on Part 2.** Either reduce H2 to N ≥ 30 (with phylogenetic-signal test on that reduced N) or commit additional Week 1–3 effort to ensure 50+ cases achievable.

**On the "overreaction" question the user asked:** v4 is NOT an overreaction that threw away good assets. The policy/humanities framing genuinely was dragging the v3.x paper below the desk-reject waterline at NHB and HSSC. The 20-case animal meta + MR chains + axiomatic framework are preserved. What v4 has NOT adequately done is **replace** the dropped T2 theorem with a new centrepiece of comparable formal weight. H3's phylogenetic signal test is a smaller centrepiece than T2 was. This is why the score is 52, not 70.

**On the lit-specialist's "safe" claim:** I partially disagree. The specialist is correct that no *published* paper makes this exact triple claim. The specialist is under-calibrated on (a) the convergence-vs-conservation data tension in Part 3, (b) the unverified preprint collision risk, and (c) the gap between Hale & Swearer 2016 and this paper being smaller than presented. Literature-specialist is not lying; literature-specialist is optimistic.

**Bottom line:** Do not submit to Proc B at 52. Execute Paths A+B+C over 3 weeks. Re-audit. Then submit.

---

*Audit completed 2026-04-21 by novelty-audit agent as independent evaluator per Stage-Gate SOP v1.0. This evaluation does not endorse the research-director or literature-specialist assessments and may be overridden only by explicit PI + co-author signoff, with signoff logged in WORKLOG.md.*
